A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD)
in the following tumor types: endometrial cancer (EC); head and neck squamous cell
carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC);
hepatocel...
Age: 18 years - 66+
Gender: All
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
The purpose of this study is to assess the patient's preference for nivolumab
subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide
patient experience data by route of administration. This study will also generate safety
data which w...
Age: 18 years - 66+
Gender: All
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and
confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients
with three distinct separate tumor cohorts. The cancers types are colorectal, head and
neck ...
Age: 18 years - 66+
Gender: All
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
The purpose of this observational research study is to follow participants who have been
treated with either bel-sar or received alternate treatment (sham, standard of care
therapy, etc.) while participating in a previous Aura Biosciences clinical research study
to a...
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for ...
Age: 12 years - 66+
Gender: All
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the most appropriate dose for the combination of
ibrutinib and pembrolizumab and to see if the combination is active for the disease. The
study will monitor for any side effects and if the combination of ibrutinib and pembro...
Age: 18 - 99 years
Gender: All
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
The purpose of this study is to determine the initial safety profile and initial antitumor
activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab]
with investigational drugs [TAK-580, TAK-202 (plozalizumab), vedolizumab]) in the 3 ...
Age: 18 years - 66+
Gender: All